Market Overview

With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI

Share:
With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI
Related AGN
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
6 Biggest Foreign Acquisitions Of American Companies In History
Top 10 Net Payout Yields For February 2017 (Seeking Alpha)
Related
President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'
Jim Cramer Shares His View On Mattel And AbbVie
Incyte: Many Strengths, Small EPS, So What's It Worth? (Seeking Alpha)

In a report published Monday, Evercore ISI analyst Umer Raffat said that with its capital structure being “reloaded” following the deal with Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), global pharma giant Allergan PLC (NYSE: AGN) is now set to “further accelerate” its strong growth profile.

The Teva deal added about $36 billion to Allergan’s capital structure. Since Allergan is committed to investment grade credit rating, it is likely to keep a portion of the proceeds to pay down debt, analyst Umer Raffat said.

Raffat believes that Allergan would also deploy capital to build on its “proven track record of creating shareholder value” by:

  • Adding scale in existing therapeutic areas
  • Expanding into new therapeutic areas and geographies
  • Undertaking “transformational” M&A activities

Answering a question regarding the kind of deals Allergen would be interested in, CEO Brent Saunders stated that it all boils down to strategic fit and price, while adding that they were “tracking companies from both categories.”

In the report Evercore ISI noted their buyside survey showed the “top takeout targets” as Biogen Inc (NASDAQ: BIIB), AbbVie Inc (NYSE: ABBV), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and a combination with Pfizer Inc. (NYSE: PFE).

Investors seemed to want to know whether Allergen would go for a large deal before the Teva generics deal closes in 1Q15. Saunders responded by saying that it would depend on the “structure of deal.”

Image credit: Public Domain

Latest Ratings for AGN

DateFirmActionFromTo
Nov 2016Morgan StanleyMaintainsOverweight
Oct 2016BarclaysAssumesEqual-Weight
Aug 2016MizuhoUpgradesNeutralBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Evercore ISIAnalyst Color Biotech Long Ideas Analyst Ratings Movers Trading Ideas General Best of Benzinga

 

Related Articles (AGN + ABBV)

View Comments and Join the Discussion!